Sandoz Inc. makes it easier to swallow the cost of prescription medicines. As the US arm of Swiss giant Novartis' generic Sandoz International division, the firm is one of the largest generic drugmakers in the US, manufacturing and selling more than 200 generic oral-dosage drugs. The company's product portfolio includes drugs to fight infections, cancers, respiratory ailments, cardiovascular and gastrointestinal disorders, and central nervous system (CNS) diseases. The Sandoz organization markets its products to wholesalers and retailers, as well as directly to consumers, physicians, and hospitals. Sandoz Inc. operates two manufacturing facilities in the US.
The company has a portfolio of approximately 1,000 compounds. The US-based firm does more than just manufacture and market its parent's drugs. It is active in the research and development of new generics, shepherding them through testing and FDA approval, and finally handling the manufacturing, packaging, and distribution of the drugs, including enoxaparin sodium injection, the first generic version of Lovenox, and Omnitrope, the first follow-on biologic available in the US. Sandoz Inc. has also experienced growing sales of its anti-infective products, such as amoxicillin and azithromycin.
Parent Sandoz International sells its products in more than 130 countries.
In 2014 Sandoz International accounted for 18% of parent Novartis' net sales.
Sandoz International has been a frontrunner in establishing a presence in the tricky generic biotechnological drug industry; such generic versions of complex pharmaceuticals are often referred to as follow-on biologics or biosimilars and require costly R&D and manufacturing processes. So far, Sandoz, Inc. only offers one generic biotech drug, a recombinant growth hormone called Omnitrope (a follow-on of Somatropin), but it is working to gain FDA approval of additional biologics.
The Sandoz organization also regularly develops and launches traditional small molecule generic drugs.
In 2015 the company received the US approval of Glatopa, the first generic version of Teva's Copaxone (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy.
In 2014 Sandoz introduced of its generic dexmedetomidine hydrochloride injection into the US market. This product is a generic version of Hospira's PRECEDEX; decitabine for injection, a generic version of Eisai's DACOGEN.
In 2014 Sandoz launched 28 new products in the US including authorized generic versions of its Pharmaceuticals Division products Diovan (valsartan), Focalin XR (dexmethylphenidate ER) and TOBI (tobramycin inhalation solution, USP); as well as cyclophosphamide injection, USP; calcipotriene and betamethasone dipropionate ointment (Taclonex, Leo Pharma); adapalene gel (Differin, Galderma Laboratories); lansoprazole capsules, amoxicillin capsules, USP, and clarithromycin tablets, USP (PREVPAC, Takeda Pharmaceuticals); the injectable decitabine (Dacogen, Eisai), and Kerydin (tavaborole) topical solution, 5% after obtaining exclusive rights from Anacor Pharmaceuticals to commercialize it in the US through Sandoz's branded dermatology business, PharmaDerm.
That year Sandoz also reached an agreement with Upsher-Smith to obtain exclusive US distribution rights for its branded potassium chloride product line, Klor-Con.
In 2012 the firm launched docetaxel injection, the generic version of cancer drug Taxotere, as well as respiratory drug formulations of albuterol sulfate and ipratropium bromide.
Through its 2012 acquisition of private drugmaker Fougera Pharmaceuticals for $1.5 billion, Sandoz became the leading global provider of generic dermatology medicines. The acquisition added manufacturing, R&D, and sales operations in New York, including the PharmaDerm branded generics subsidiary. Following the transaction, Fougera becomes part of the Sandoz Inc. organization, serving as the headquarters for Sandoz's global dermatology business.
Other purchases include the 2011 acquisition of Falcon Pharmaceuticals, the former generic ophthalmic drugmaking unit of Alcon. In 2010 it added respiratory drugs to its development pipeline through the acquisition of US-based Oriel Therapeutics.
Formerly named Geneva Pharmaceuticals, the company was brought under the Sandoz name in 2003 as Novartis sought to consolidate its generics businesses. Novartis later acquired Eon Labs in 2005 and integrated it into Sandoz Inc. to further strengthen its position in the US generic pharmaceutical market.